Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - First-in-Human Treatment with HG-CT-1

Company: HEMOGENYX PHARMACEUTICALS PLC Date: 2025-02-24 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 National Storage Mechanism | Additional information ![](https://tracker.live.rns-distribution.com/track.live-rns/5549223_d9353a075fe0b610698e373da828b7e4.png)

RNS Number : 1775Y

Hemogenyx Pharmaceuticals PLC

24 February 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

24 February 2025

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

First-in-Human Treatment with HG-CT-1 for Relapsed or Refractory Acute Myeloid Leukemia

**Hemogenyx Pharmaceuticals plc** (LSE: HEMO) is pleased to announce the administration of its **first-in-human** dose of **HG-CT-1** , its proprietary CAR-T cell therapy, for the treatment of **relapsed or refractory acute myeloid leukemia (R/R AML) in adults** . This marks a major milestone in the Company's clinical development program, demonstrating progress toward delivering a potentially life-saving treatment for AML patients with limited therapeutic options.

Further updates on the clinical trial will be provided in due course.

**Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:**  

*"We are thrilled to take this critical step in advancing the development of HG-CT-1. This milestone not only validates our years of research and development, but also brings us closer to providing a transformative treatment for patients suffering from relapsed or refractory AML."*

   

Enquiries:

|     |     |
| --- | --- |
| Hemogenyx Pharmaceuticals plc | [https://hemogenyx.com](https://hemogenyx.com/) |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | [headquarters@hemogenyx.com](mailto:headquarters@hemogenyx.com) |
| Peter Redmond, Director | [peter.redmond@hemogenyx.com](mailto:peter.redmond@hemogenyx.com) |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Adam Cowl |     |
| Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey, Charles Goodfellow |     |

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com/).  

  

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](https://www.lseg.com/privacy-and-cookie-policy).

END

MSCPPUPGPUPAPPW

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.